TickerFacts.

Insight Molecular Diagnostics Inc. (IMDX): Revenue

Annual figures by period end, from SEC filings.

$4.05M
Year ended 2025-12-31
$1.67M
Trailing 12 months to 2026-06-30
+61.8%
3-year compound annual growth
+27.2%
5-year compound annual growth
2020-12-31: $1.22M2021-12-31: $2.20M2022-12-31: $958.0K2023-12-31: $1.50M2024-12-31: $1.88M2025-12-31: $4.05M$4.05M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$4.05M+115.6%2026-03-26, From 2025-01-01
2024-12-31$1.88M+25.1%2026-03-26, From 2024-01-01
2023-12-31$1.50M+56.9%2025-03-24, From 2023-01-01
2022-12-31$958.0K-56.4%2024-04-16, From 2022-01-01
2021-12-31$2.20M+80.8%2023-04-12, From 2021-01-01
2020-12-31$1.22Mn/a2022-03-11, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$4.05M+115.6%
Biomerica Inc (BMRA)2026-05-31$4.45M-16.2%
Anbio Biotechnology (NNNN)2025-12-31$8.65M+5.6%
Aspira Women's Health Inc. (AWHL)2025-12-31$9.22M+0.4%
Volitionrx Ltd (VNRX)2025-12-31$1.73M+40.0%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$1.54M-78.0%
Immucell Corp (ICCC)2025-12-31$27.64M+4.3%
Alpha Teknova, Inc. (TKNO)2025-12-31$40.52M+7.4%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$67.67M+16.9%

Compare IMDX, BMRA, NNNN, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗